Veregen sinecatechins regulatory update

Medigene said Veregen sinecatechins to treat external genital and perianal warts in immunocompetent patients ages >=18 was recommended for approval under the EU’s Mutual Recognition Procedure in 8 countries. The company expects to begin the launch of the drug in the countries next half. The countries comprise the U.K., Ireland, Italy, Portugal, Croatia, Latvia, Lithuania and Estonia. The topical formulation of polyphenols extracted from green tea leaves is marketed in the U.S., Canada, Taiwan and 15 European countries. ...